Check out your Company Bowl for anonymous work chats.
Congratulations to Christopher Girardi, our Head of Performance Marketing, for being named to MM+M's 40 under 40 list. This award recognizes marketers whose leadership and strategic thinking have contributed to significant organizational-wide growth. We are proud of the work Chris and his team are doing to drive Verily’s data-driven clinical research recruitment efforts. Through the use of strategic marketing tactics, Chris and his team are connecting precisely the right people to clinical trials and studies to accelerate recruitment of more representative, engaged populations. Congratulations to Chris and all the other honorees! https://bit.ly/47psOsh #MMM40Under40 #ClinicalResearch #PrecisionHealth
Happy Diwali! Enjoy these photos from our office celebrations filled with sweets, rangoli making, and henna workshops. hashtag#LifeAtVerily
Today, we announced that the Centers for Disease Control and Prevention (CDC) selected Verily to support the agency’s National Wastewater Surveillance System (NWSS). The NWSS will utilize Verily’s Wastewater program to detect the spread of pathogens present in wastewater samples, including SARS-CoV-2 and MPXV. “Supporting the CDC and NWSS significantly extends Verily’s footprint as a leading provider in real-time wastewater surveillance in the U.S. and reinforces our vision of impacting public health worldwide,” said Andrew Trister, MD PhD, Chief Scientific Officer at Verily. Read more about the multi-year collaboration:
Congratulations to Vindell Washington, our Chief Clinical Officer for Care Delivery and Director of the Health Equity Center of Excellence, for being named one of Fierce Healthcare's Most Influential Minority Executives in Healthcare! This award recognizes leaders who have had a measurable impact on the healthcare industry in the last year. We are proud of the work Vindell and his team are doing to address health equity through the use of innovative technology and the publication of standard practices to increase diversity, equity, and inclusion in clinical trials. #PrecisionHealth
We are honored to receive two IDEA awards – a Bronze in the health category and a People’s Choice for the design of Verily Retinal Camera! This prestigious achievement reflects our team’s dedication to building tools that advance precision health for all. The intuitive design of the Verily Retinal Camera enables greater access to precision retinal imaging for patients by conducting them in convenient locations, such as primary care settings.
Happy 8th birthday, Verily! Eight years ago, Verily was born out of Google X, the moonshot factory, with the aim of transforming healthcare. In 2016, we were founded as Verily Life Sciences, an Alphabet Inc. company. Since that time, Verily has evolved as a precision health tech company, focused on research, care, and health financing. Across all that we do, we’re helping to close the gap between research and care by creating new tools to accelerate evidence generation, products to enable more personalized care, and approaches that make costs more predictable. Cheers to 8 years!
Big news! Verily Retinal Camera won two honorable mentions in Fast Company’s 2023 Innovation by Design Awards - Best Design North America and Health categories. We are proud to be recognized alongside designers and businesses who are solving the problems of today and tomorrow. See the full list of #FCDesignAwards winners: https://lnkd.in/ePbEBrST Learn about Verily Retinal Service!
The National Academies of Sciences, Engineering, and Medicine published a framework and recommendations, co-authored by Amy Abernethy, Verily's President of Product Development & Chief Medical Officer for addressing equity issues across the innovation ecosystem to ensure medical advancements work for all people. Fast-paced technological innovation has the potential to transform health and medicine, but it also raises important social and ethical concerns. This report is an important step in addressing this complexity.
We are proud to announce a new strategic partnership with OneOncology to accelerate clinical trials and advance cancer research. Our clinical trial management software (CTMS) SignalPath will be integrated across OneOncology Research Network sites, enabling improved infrastructure, streamlined regulatory processes, and increased collaboration with sponsors. “We can help enhance our partners’ clinical trial programs, which ultimately better democratizes clinical trials, and improves health equity,” said Dr. Davey Daniel, Chief Medical Officer, OneOncology.
"Verily Hires Former Apple Health Leader Andrew Trister as Chief Scientific Officer" - We are excited to announce that Andrew Trister, an oncologist and veteran of big technology companies and research, has joined Verily as our new CSO. Trister will lead Verily’s population health initiatives, including public health solutions like the company’s ongoing work to combat disease-carrying mosquito populations and a program that helps wastewater treatment plants monitor for pathogens. Trister's focus on public health will build on his recent role as a deputy director at the Bill and Melinda Gates Foundation, where he led digital health.
